Fri, August 11, 2023

David Nierengarten Maintained (STRO) at Buy with Decreased Target to $12 on, Aug 11th, 2023

David Nierengarten of Wedbush, Maintained "Sutro Biopharma, Inc." (STRO) at Buy with Decreased Target from $20 to $12 on, Aug 11th, 2023.

David has made no other calls on STRO in the last 4 months.



There is 1 other peer that has a rating on STRO. Out of the 1 peers that are also analyzing STRO, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $17 on, Tuesday, June 27th, 2023